| Market Cap | 14.06M | P/E | - | EPS this Y | 49.20% | Ern Qtrly Grth | - |
| Income | -14.19M | Forward P/E | -1.81 | EPS next Y | 31.60% | 50D Avg Chg | 19.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -14.00% |
| Dividend | N/A | Price/Book | 0.70 | EPS next 5Y | - | 52W High Chg | -93.00% |
| Recommedations | 1.50 | Quick Ratio | 4.05 | Shares Outstanding | 1.18M | 52W Low Chg | 65.00% |
| Insider Own | 1.82% | ROA | -58.53% | Shares Float | 1.16M | Beta | 1.30 |
| Inst Own | 2.89% | ROE | -110.09% | Shares Shorted/Prior | 56.10K/60.22K | Price | 2.10 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 334,030 | Target Price | 33.75 |
| Oper. Margin | - | Earnings Date | Nov 7 | Volume | 83,976 | Change | -0.94% |
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.
| Maxim Group | Buy | May 1, 24 |
| Maxim Group | Buy | Apr 16, 24 |
| Maxim Group | Buy | Nov 17, 23 |
| Ladenburg Thalmann | Buy | May 16, 23 |
| Maxim Group | Buy | Mar 30, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Finley John David | CEO, CFO, Director CEO, CFO, Director | Jan 31 | Buy | 0.559 | 10,000 | 5,590 | 74,649 | 02/01/24 |
| Williams Donald Allen | Director Director | Jan 31 | Buy | 0.605 | 10,000 | 6,050 | 30,000 | 02/01/24 |
| Finley John David | CEO, CFO, Director CEO, CFO, Director | Dec 11 | Option | 0.00 | 5,559 | 63,340 | 12/19/23 | |
| Williams Donald Allen | Director Director | Sep 27 | Buy | 0.54 | 20,000 | 10,800 | 20,000 | 09/29/23 |
| Finley John David | CEO, CFO, Director CEO, CFO, Director | Sep 27 | Buy | 0.5392 | 15,000 | 8,088 | 43,394 | 09/29/23 |
| Trenschel Robert J. | Director Director | Sep 14 | Sell | 0.64 | 300 | 192 | 09/15/23 | |
| Finley John David | CEO, CFO, Director CEO, CFO, Director | Sep 13 | Buy | 0.655 | 15,000 | 9,825 | 28,394 | 09/14/23 |
| Finley John David | Chief Financial Offi.. Chief Financial Officer | Sep 01 | Buy | 0.1437 | 19,481 | 2,799 | 148,727 | 09/02/22 |
| Hallam Thomas | Chief Executive Offi.. Chief Executive Officer | Aug 16 | Buy | 0.25 | 40,000 | 10,000 | 57,592 | 08/18/22 |
| Finley John David | Chief Financial Offi.. Chief Financial Officer | Aug 16 | Buy | 0.25 | 100,000 | 25,000 | 121,896 | 08/18/22 |
| Dawson Michael John | Chief Medical Office.. Chief Medical Officer | Mar 29 | Buy | 1.1395 | 15,000 | 17,092 | 15,000 | 03/31/22 |
| Hallam Thomas | Chief Executive Offi.. Chief Executive Officer | Mar 28 | Buy | 1.18 | 10,000 | 11,800 | 17,592 | 03/29/22 |
| Finley John David | Chief Financial Offi.. Chief Financial Officer | Mar 24 | Buy | 1.0899 | 7,500 | 8,174 | 21,896 | 03/25/22 |
| Trenschel Robert J. | Director Director | Sep 13 | Buy | 2.83 | 14,999 | 42,447 | 14,999 | 09/13/21 |
| Finley John David | Chief Financial Offi.. Chief Financial Officer | Aug 30 | Buy | 2.64 | 10,000 | 26,400 | 12,396 | 08/30/21 |